Stock BIOL BIOLASE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings BIOLASE, Inc.

Equities

BIOL

US0909117022

Real-time Estimate Cboe BZX
Other stock markets
 12:05:30 2024-04-29 pm EDT 		5-day change 1st Jan Change
0.145 USD -2.03% Intraday chart for BIOLASE, Inc. -2.00% -86.90%
Apr. 01 Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating MT
Mar. 22 Wall Street Set to Open Marginally Lower Friday Following Powell Speech, After Hitting Record Highs Thursday MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
BIOLASE, INC. Stock BIOLASE, Inc.
-86.90% 4.92M -
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.97% 219B
B
DANAHER CORPORATION Stock Danaher Corporation
+7.35% 183B
B-
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.12% 133B
B-
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+25.25% 108B
A-
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+0.27% 63.06B
A-
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+12.34% 52.02B
B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.62% 48.2B
B+
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
+0.15% 40.37B
A
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+13.21% 39.35B -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BIOL Stock
  4. Ratings BIOLASE, Inc.